Alkem launches Perampil at affordable prices and improved patient access for epilepsy treatment in India

Alkem Laboratories Ltd. (Alkem), one of the India's leading pharmaceutical formulation development, manufacturing, and marketing companies, announces the launch of Perampil (Perampanel) tablets 2 mg/4 mg/6 mg on June 9th 2021 to make the treatment accessible to patients and healthcare providers improving their quality of life. Alkem has launched Perampil, at 2 mg - Rs. 49/strip of 7 tablets, 4 mg - Rs. 180/strip of 15 tablets and 6 mg - Rs. 300/strip of 15 tablets, to improve patient access.

This product reaffirms Alkem's commitment towards improving epilepsy care by bringing multiple treatment options of quality products to patients and health care professionals in India. Alkem had also launched Brivasure (Brivaracetam) tablets in March 2021 for the adjunctive management of partial onset seizure with or without secondary generalization.

The drug, Perampanel, has been approved by the Drugs Controller General of India (DCGI), as an adjunctive therapy in treatment of partial onset seizures in patients with epilepsy aged 4 years and older and also as an adjunctive therapy in treatment of primary generalized tonic-clonic seizures in patients with epilepsy aged 12 years and older. Alkem continues to work persistently towards the production of top-quality products to improve patient access and quality of life for them.

Shares of Alkem Laboratories Ltd was last trading in BSE at Rs.3110 as compared to the previous close of Rs. 3171.85. The total number of shares traded during the day was 9168 in over 1583 trades.

The stock hit an intraday high of Rs. 3223.65 and intraday low of 3061.35. The net turnover during the day was Rs. 28868592.

Source : Equity Bulls

Keywords